Genomics Companies Dominate Q2 Pharma M&A Activity | GenomeWeb

NEW YORK, July 3 – Three out of four of the largest mergers and acquisitions that occurred in the pharmaceutical sector in the second quarter involved genomics companies, and the consolidation trend is expected to continue, said Steven Burrill, CEO of Burrill & Company, a San Francisco-based merchant bank.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."